Roivant Sciences
ROIV | NASDAQ
$38.61
-$0.92 (-2.33%)
At close: Nov 16, 2026, 4:00 PM ET
$39.11
+$0.50 (+1.30%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Roivant Sciences Company Profile
Company profile explainedCompany Profile
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Key Executives
| Name | Position |
|---|---|
| Eric Venker | President & Chief Executive Officer of Immunovant |
| Matthew Gline | Chief Executive Officer & Director |
| Ian Rosenblum | Chief Information Officer |
| Richard Pulik | Chief Financial Officer |
| Alex Gasner | Executive Vice President of Roivant Health |
| Frank Torti | President & Vant Chair |
| Jennifer Humes | Chief Accounting Officer |
| Kelly Graff | Head of People |
| Mayukh Sukhatme | President, Chief Investment Officer & Director |
| Sam Kaplan | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 4 | Filing |
| Oct 27, 2026 | 4 | Filing |
| Oct 27, 2026 | 4 | Filing |
| Oct 27, 2026 | 4 | Filing |
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 22, 2026 | 4 | Filing |
| Oct 21, 2026 | 8-K | Current Report |
| Oct 20, 2026 | 4 | Filing |
| Oct 20, 2026 | 4 | Filing |
| Oct 05, 2026 | SC 13D/A | [Amend] Filing |
Roivant Sciences
| Country | United Kingdom |
| IPO Date | Dec 8, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 721 |
| CEO | Matthew Gline |
Stock Details
| Ticker Symbol | ROIV |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001635088 |
| CUSIP Number | G76279101 |
| ISIN Number | BMG762791017 |
| SIC Code | 2834 |
Recent News
- 5 days ago / seekingalpha.comDon't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum
- 6 days ago / globenewswire.comPriovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
- 7 days ago / seekingalpha.comRoivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
- 8 days ago / marketbeat.comRoivant Sciences Q2 Earnings Call Highlights
- 8 days ago / zacks.comRoivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
- 26 days ago / seekingalpha.comRoivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript
- 27 days ago / marketbeat.comRoivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
- 27 days ago / globenewswire.comRoivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
- 2 months ago / marketbeat.comRoivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
- 2 months ago / globenewswire.comRoivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Add to Watchlist
Select watchlists to add or remove ROIV